Skip to main content
Message Font: Serif | Sans-Serif
No. of Recommendations: 0
Ok, Ok so there was a 1.7MM exceptional sale and it includes the interest income off of over $100MM in cash - but hey, how many biotechs can post the following headline:

Aurora Biosciences Reports Financial Results for Second Quarter 2000; Third Consecutive Profitable Quarter

PR Newswire
SAN DIEGO, Jul 31, 2000 /PRNewswire via COMTEX/ -- Aurora Biosciences
Corporation (Nasdaq: ABSC) today announced financial results for the second
quarter ended June 30, 2000. Net income for the second quarter 2000 was $4.2
million, or $0.19 per share on a diluted basis, compared to a net loss of $0.4
million, or $0.03 per share, for the second quarter 1999. Revenue increased 34%
to $17.5 million for the second quarter 2000 compared to $13.0 million for the
second quarter 1999.

For the six-month period ended June 30, 2000, net income was $4.3 million, or
$0.20 per share on a diluted basis, compared to a net loss of $4.9 million, or
$0.29 per share, for the same period in 1999. Revenue increased 55% to $30.3
million for the six-month period compared to $19.6 million for the same period
in 1999.

"We continue to be pleased with the growth of our core businesses. Our top-line
growth was strong, and we increased our cash position by $2.2 million, to over
$107 million," commented Stuart J.M. Collinson, Ph.D, Aurora's chairman, chief
executive officer and president. "We believe that Aurora is well positioned to
capitalize on the opportunities that have been created through the sequencing of
the human genome. We intend to leverage our formidable technological assets such
as the UHTSS(TM) Platform, proprietary fluorescence assays, ion channel
technology and functional genomics initiatives to take the science of drug
discovery to the next level."

The revenue growth in the second quarter resulted from a new ion channel
discovery collaboration with Johnson and Johnson and our continuing
collaborations with Pfizer, American Home Products and Glaxo Wellcome. Cost of
revenue increased due to the growth in revenue and other expenses increased with
the overall growth of the company. Net interest and other income increased
significantly due to increased cash and investments resulting from a $71 million
private placement of common stock in February 2000. Also contributing to the
increase in other income was the recognition of a gain of $1.7 million from the
sale of shares of Cytovia, Inc. to Maxim Pharmaceuticals.

The Company's quarterly and annual financial performance may be subject to
fluctuations depending on factors such as revenue recognized from contracts and
collaborations, timing of the delivery of technologies and systems, the
completion of contracted service commitments to Aurora's customers and potential
future acquisitions of complimentary assets or technologies. Accordingly,
revenue and operating results for prior periods may not be predictive of
Aurora's future financial results.

Aurora designs, develops and commercializes advanced drug discovery
technologies, services and systems to accelerate the discovery of new medicines.
The Company's core technologies include a broad portfolio of proprietary
fluorescence assay technologies, including its GeneBLAzer(TM) and VIPR(TM)
technologies, its functional genomics GenomeScreen(TM) program, its automated
master compound store, the AMCS, and its ultra-high throughput screening system
(UHTSS(TM) Platform) and subsystems to miniaturize and automate drug screening
and profiling assays derived from those technologies. Aurora technologies have
been commercially validated by over 15 major life sciences companies and
research organizations, including American Home Products, Bristol-Myers Squibb
Co., Cystic Fibrosis Foundation, Eli Lilly & Co., Glaxo Wellcome, Genentech,
Inc., Johnson & Johnson, Merck & Co., Inc., NV Organon Laboratories, Pfizer,
Inc., and Warner-Lambert Company, in the form of commercialization agreements
for discovery services, licenses or systems. For additional information on
Aurora's services and products, please contact Sales and Marketing via email at

Statements in this press release that are not strictly historical are
"forward-looking" statements which involve a high degree of risk and
uncertainty. Such forward-looking statements include statements regarding future
revenue, costs and profitability, continued commercialization and expansion of
Aurora's research programs and customer base, and potential acquisitions and
strategic opportunities. Such statements reflect corporate goals or objectives
and the actual events or results may differ materially from those described in
such forward-looking statements. Factors that could cause or contribute to
differences include risks regarding the ability to attract additional customers;
risks relating to potential strategic transactions that the Company may
undertake or investments or acquisitions the Company may make; the Company's
dependence on existing and future pharmaceutical and biotechnology
collaborations; the Company's ability to timely complete the development,
manufacture and assembly of its technologically complex UHTSS Platform and AMCS
system; the Company's new and uncertain technology; the Company's dependence on
patents and proprietary rights; and the development or availability of competing
systems. These factors and others are more fully described in the Company's
Annual Report on Form 10-K/A for the fiscal year ended December 31, 1999, and
subsequent Forms 10-Q, as filed with the Securities and Exchange Commission. For
additional corporate information, visit the Aurora website at

GeneBLAzer(TM), GenomeScreen(TM), UHTSS(TM) and VIPR(TM) are trademarks of

(In thousands, except per share amounts)

Statement of
Operations data: Quarters ended Six months ended
June 30, June 30,
2000 1999 2000 1999
(Unaudited) (Unaudited)

Revenue $17,529 $13,042 $30,329 $19,561

Operating expenses:
Cost of revenue 9,172 7,241 16,976 13,167
Research and
development 3,393 3,213 6,012 6,065
Selling, general
and administrative 3,835 3,191 7,102 5,565
Total operating
expenses 16,400 13,645 30,090 24,797

Interest and
other, net 3,343 170 4,261 379
Income (loss)
before taxes 4,472 (433) 4,500 (4,857)
Income taxes (240) -- (240) --
Net income (loss) $4,232 $(433) $ 4,260 $(4,857)

Basic net income (loss)
per share $0.21 $(0.03) $0.22 $ (0.29)

Diluted net income (loss)
per share $0.19 $(0.03) $0.20 $ (0.29)

Weighted-average shares

Basic 19,959 16,897 19,293 16,817

Diluted 22,227 16,897 21,769 16,817

Balance Sheet data: June 30, 2000 Dec. 31, 1999

Cash, cash equivalents and investments $107,698 $36,618
Total assets 150,881 63,862
Capital lease and loan obligations,
less current portion 4,588 4,343
Accumulated deficit (17,319) (21,579)
Total stockholders' equity 121,668 40,314

SOURCE Aurora Biosciences Corporation

CONTACT: Doug Farrell, Senior Director, Investor Relations & Corporate
Communications of Aurora Biosciences Corporation, 858-404-6767, fax,


(C) 2000 PR Newswire. All rights reserved.

Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.